Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme

  1. Wirth, M.
  2. Tyrrell, C.
  3. Delaere, K.
  4. Sánchez-Chapado, M.
  5. Ramon, J.
  6. Wallace, D.M.A.
  7. Hetherington, J.
  8. Pina, F.
  9. Heyns, C.
  10. Borchers, T.
  11. Morris, T.
  12. Armstrong, J.
Aldizkaria:
Prostate Cancer and Prostatic Diseases

ISSN: 1365-7852,  1476-5608

Argitalpen urtea: 2005

Alea: 8

Zenbakia: 2

Orrialdeak: 194-200

Mota: Artikulua

DOI: 10.1038/SJ.PCAN.4500799 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus